The Fifth China-ASEAN Pharmaceutical Cooperation and Development Summit Forum Held

Release time:


From September 20 to 21, the 5th China-ASEAN Pharmaceutical Cooperation and Development Summit Forum, co-sponsored by the State Drug Administration of China and the People's Government of Guangxi Zhuang Autonomous Region, was held in Nanning. Jiao Hong, director of the State Food and Drug Administration, and Li Bin, vice chairman of Guangxi Zhuang Autonomous Region, attended the forum and delivered speeches.

The forum is divided into drug supervision, drug supervision science and innovation, new progress in drug quality control technology, and dialogue on the development of drug industry cooperation. Representatives from drug regulatory agencies of China and 10 ASEAN countries, World Health Organization institutions in China, domestic and foreign drug production and operation enterprises, etc., focused on the theme of "drug regulatory innovation and high-quality industrial development". Exchange and discuss drug regulatory policies, industrial R & D innovation, regional industrial cooperation and other issues. On the basis of drug cooperation, this forum included the relevant contents of cosmetics supervision for the first time.

Jiao Hong pointed out at the forum that the amendments to the Drug Administration Law and the Vaccine Administration Law will be formally implemented on December 1 this year, and the State Food and Drug Administration will speed up the revision of supporting rules and regulations, strengthen publicity and training, constantly improve the regulatory system and mechanism, provide institutional guarantee for the high-quality development of the industry, deepen the reform of the review and approval system, speed up innovation and clinical urgent drug approval and marketing, and optimize the review process, refine and improve relevant evaluation requirements and guiding principles, create a policy environment conducive to encouraging innovation, so that the public can use new drugs and good drugs in a timely manner; strengthen the supervision of the whole life cycle of drugs, emphasize problem orientation, focus on risk management, urge drug marketing license holders to implement the main responsibility, implement the State Office's "opinions on establishing a professional and specialized drug inspector team", strengthen the construction of drug inspector team, and more effectively ensure the safety of drug use by the public; continue to carry out regulatory scientific research, rely on regulatory scientific research bases, accelerate the development of new standards, new tools and new methods, continue to improve the scientific level of drug supervision, and lay a solid foundation for more effective full life cycle supervision; deeply participate in international exchanges and cooperation, actively participate in the revision of relevant global rules and technical standards, and actively propose more and more effective coordination plans, and contribute Chinese wisdom and strength to the cause of global health.

Jiao Hong said that China will actively carry out exchanges with the drug regulatory agencies of ASEAN countries in policies, regulations, and regulatory practices to enhance understanding, resolve concerns, promote industrial cooperation, and promote more high-quality pharmaceutical products to enter the Chinese and ASEAN markets. Contribute to the health cause of all countries.

Li Bin proposed to expand drug safety cooperation between China and ASEAN, promote the pharmaceutical industry to become bigger and stronger, and strengthen the exchange and training of pharmaceutical professionals.

Heads of relevant departments, bureaus and directly affiliated units of the State Food and Drug Administration, and representatives of drug regulatory agencies of various provinces (autonomous regions and municipalities) attended the meeting.

The China-ASEAN Pharmaceutical Cooperation and Development Summit Forum is a high-level forum under the framework of the China-ASEAN Expo. It has been held for 5 sessions since 2011. Participants are from drug regulatory agencies of ASEAN countries, the World Health Organization, research institutions, universities, and large multinational companies. And industry associations. Through the platform of the forum, the participants have a more comprehensive and in-depth understanding of the drug regulatory situation in various countries, promoted mutual trust, enhanced confidence in cooperation, and formed a consensus on strengthening drug safety cooperation and promoting bilateral and multilateral pharmaceutical trade.